José
Palacios Calvo
Profesor/a Titular Universidad
Hospital Miguel Servet
Zaragoza, EspañaPublications en collaboration avec des chercheurs de Hospital Miguel Servet (8)
2021
-
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888
2020
-
Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences
American Journal of Surgical Pathology, Vol. 44, Núm. 5, pp. 649-656
2017
2016
-
High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer
Oncologist, Vol. 21, Núm. 2, pp. 150-155
2012
-
Classical markers like ER and Ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: Results from the GEICAM/2002-01 phase II study
Clinical and Translational Oncology, Vol. 14, Núm. 6, pp. 430-436
-
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers
BMC Medical Genomics, Vol. 5
2008
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814
2007
-
Gene expression profiling of breast cancer cells in response to gemcitabine: NF-κB pathway activation as a potential mechanism of resistance
Breast Cancer Research and Treatment, Vol. 102, Núm. 2, pp. 157-172